Join Growin Stock Community!

Radiopharm theranostics limitedRADX.US Overview

US StockHealthcare
(No presentation for RADX)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

RADX AI Insights

RADX Overall Performance

RADX AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

RADX Recent Performance

-0.50%

Radiopharm theranostics limited

0.05%

Avg of Sector

-0.31%

S&P500

RADX PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

RADX Key Information

RADX Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

RADX Profile

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting avß6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, an avß6-integrin targeting agent for the treatment of multiple cancer types; RAD 101 and RAD 102 for brain metastases; RAD 402 to treat advanced prostate cancer; and RV01 for multiple solid tumors. It has strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

Price of RADX

RADX FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

RADX Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1

No related data records

  • When is RADX's latest earnings report released?

    The most recent financial report for Radiopharm theranostics limited (RADX) covers the period of 2025Q2 and was published on 2024/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating RADX's short-term business performance and financial health. For the latest updates on RADX's earnings releases, visit this page regularly.

  • How much debt does RADX have?

    As of the end of the reporting period, Radiopharm theranostics limited (RADX) had total debt of 32.1M, with a debt ratio of 0.32. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does RADX have?

    At the end of the period, Radiopharm theranostics limited (RADX) held Total Cash and Cash Equivalents of 29.12M, accounting for 0.34 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.